Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
Peter Andreas FaschingSiddhartha YadavChunling HuMarius WunderleLothar HäberleSteven N HartMatthias RübnerEric C PolleyKun Y LeeRohan D GnanaolivuPeyman HadjiHanna HuebnerHans TeschJohannes EttlFriedrich OverkampMichael Patrick LuxArif Bülent EkiciBernhard VolzSabrina UhrigDiana LüftnerMarkus WallwienerVolkmar MuellerErik BellevilleMichael UntchHans-Christian KolbergMatthias W BeckmannAndré ReisArndt HartmannWolfgang JanniPauline WimbergerFlorin-Andrei TaranTanja N FehmDiethelm WallwienerSara Y BruckerAndreas SchneeweißAndreas Daniel HartkopfFergus J CouchPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Multigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in BRCA1/2 and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.